The most critical data point in mental health care is often the one that never gets recorded: how a patient feels on the Tuesday between monthly appointments. A new startup, Siggy, is betting that a combination of AI, wearables, and a simple daily score can capture that missing signal, giving clinicians a continuous record to work with instead of a snapshot.
Founded in late 2025, Siggy has raised a $6 million pre-seed round led by Village Global to build what it calls continuous, clinician-supervised mental health care [Crunchbase News, November 2026]. The service, which had begun accepting paying patients before its November 2026 public launch, is structured around a core premise: AI handles the persistent, low-touch monitoring, while licensed clinicians retain all diagnostic and prescribing authority [Crunchbase News, November 2026] [WebWire, November 2026].
The Clinical Data Layer
Siggy’s product begins with an AI-guided conversation to collect a patient’s history, followed by video visits with licensed clinicians for diagnosis and treatment planning, which can include medication management for non-controlled substances [WebWire, November 2026] [siggymd.ai]. The operational wedge is what happens between those appointments. Patients are prompted for daily check-ins on sleep, mood, medication adherence, and physical well-being [NewsBeep.com].
Crucially, they can also connect wearable devices from Apple Watch, Oura, and Whoop [WebWire, November 2026]. The platform synthesizes this stream of self-reported and biometric data,including activity, heart rate, and heart-rate variability,into a single, daily “Siggy Score” visible to both the patient and their care team [WebWire, November 2026]. The goal is to surface trends and potential medication side effects that might otherwise be lost in a patient’s recall during a brief visit.
A Foundational Insurance Wedge
For a digital health service targeting mainstream adoption, reimbursement is the gatekeeper. Siggy’s most significant early claim is that its service is already covered by most major insurance plans in all 50 states, including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Humana, a network the company says reaches roughly 80% of insured Americans [WebWire, November 2026]. If substantiated at scale, this coverage would be a powerful commercial accelerant, removing a primary cost barrier for patients and positioning Siggy within the existing healthcare payment flow from day one.
The company’s clinical model is carefully bounded. The AI is positioned as an information-gathering and support tool, with 24/7 availability for CBT-based conversations, while medical questions are routed to the human care team [siggymd.ai]. Patients can message their clinicians asynchronously, and the platform allows for full data deletion, addressing privacy concerns that often accompany continuous monitoring [siggymd.ai].
The Operator-Founder Pedigree
Siggy’s founding team brings a rare blend of scaled digital health operations and specialized clinical platform experience. This background is likely a key reason investors like Village Global, Albert Wenger, and Immad Akhund backed the pre-seed round [WebWire, November 2026].
| Founder | Role | Prior Venture | Key Background |
|---|---|---|---|
| Jonathan Sabbagh | Co-founder | Journey Clinical | Built a platform connecting therapists to ketamine prescribers; former finance executive [Crunchbase News, November 2026] [The Trauma Therapist Podcast]. |
| Edvard Engesæth, MD | Co-founder & COO | Nurx | Co-founded the telemedicine company Nurx, which served over two million patients and reached a $100 million annual run rate before merging with Thirty Madison [Crunchbase News, November 2026] [STAT News, February 2022]. |
| Blake Yoder | Co-founder | Not specified in sources | Listed as a co-founder on LinkedIn [LinkedIn, Blake Yoder]. |
Engesæth’s experience at Nurx, which navigated the complexities of telehealth prescribing, insurance, and patient logistics at a national scale, provides a foundational playbook. Sabbagh’s work with Journey Clinical involved building a platform at the intersection of psychotherapy and novel treatment protocols, a relevant background for managing a hybrid clinical-AI workflow.
The Risks of Continuous Monitoring
The bet on continuous data collection between visits is ambitious, but it introduces a set of clinical and engagement risks that Siggy will need to navigate. The model depends on consistent patient participation to generate meaningful longitudinal data; dropout or sporadic use would undermine the core value proposition. Furthermore, the translation of diverse data streams into a single, actionable “Siggy Score” presents a significant clinical validation challenge. The score must be demonstrably useful to clinicians in making treatment decisions without creating alert fatigue or misinterpretation.
From a competitive standpoint, the landscape for digital mental health is crowded, though Siggy’s specific focus on continuous monitoring between clinician visits carves a distinct niche. The larger challenge may be structural: integrating seamlessly into the workflows of busy clinicians and proving that the additional data leads to measurably better outcomes, which is the ultimate metric for both patients and payers.
The Next Twelve Months
The immediate roadmap will be about proving the model. The $6 million in pre-seed capital provides runway to refine the AI interactions, deepen integrations with electronic health record systems, and, most critically, gather real-world evidence on patient outcomes and clinician adoption [Crunchbase News, November 2026]. Key milestones to watch will be published data on patient engagement with the daily check-ins, and any partnerships with health systems or large provider groups that would signal clinical endorsement beyond direct-to-consumer adoption.
The company’s early insurance coverage is a formidable advantage, but it will need to demonstrate efficient billing operations and patient satisfaction to retain those payer relationships. A logical next financing step would be a seed round in late 2027 or early 2028, likely contingent on showing scaled patient growth and early signals of improved clinical efficiency or outcomes.
Siggy is squarely aimed at the vast population managing ongoing mental health conditions like depression, anxiety, and PTSD. For these patients, the current standard of care is often defined by discontinuity: periodic appointments that rely heavily on a patient’s often imperfect recollection of the weeks prior, with little objective data on daily functioning or medication response between visits. Siggy’s attempt to fill those gaps with a gentle, daily pulse check represents a pragmatic, if technologically complex, evolution of the care model. Its success will hinge not on replacing the clinician, but on making them significantly better informed.
Sources
- [Crunchbase News, November 2026] Exclusive: Nurx And Journey Clinical Co-Founders Raise $6M For Mental Health Startup Siggy | https://news.crunchbase.com/venture/nurx-journey-clinical-founders-raise-mental-health-startup-siggy/
- [WebWire, November 2026] Siggy Launches Continuous Mental Health Care, Powered by AI and Supervised by Clinicians, With a Daily Siggy Score That Tracks Your Progress | https://www.webwire.com/ViewPressRel.asp?aId=363771
- [siggymd.ai, retrieved 2026] Siggy, Continuous, clinician-supervised mental health care | https://siggymd.ai/
- [NewsBeep.com] Siggy raises $6M to bring AI check-ins between clinician visits
- [STAT News, February 2022] Nurx had cleared $100 million in sales in the year prior to February 2022
- [The Trauma Therapist Podcast, retrieved 2026] Psychedelic-Assisted Psychotherapy with Jonathan Sabbagh | https://www.thetraumatherapistproject.com/podcast/psychedelic-assisted-psychotherapy-with-jonathan-sabbagh
- [LinkedIn, retrieved 2026] Blake Yoder - Co-Founder at Sentinel | https://www.linkedin.com/in/blakeyoder/